LG Life Science LTD. - Product Pipeline Review - 2016

Published: Sep, 2016 | Pages: 71 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

LG Life Science LTD. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'LG Life Science LTD. - Product Pipeline Review - 2016', provides an overview of the LG Life Science LTD.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by LG Life Science LTD., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of LG Life Science LTD.
- The report provides overview of LG Life Science LTD. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses LG Life Science LTD.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features LG Life Science LTD.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate LG Life Science LTD.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for LG Life Science LTD.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding LG Life Science LTD.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 6
LG Life Science LTD. Snapshot 7
LG Life Science LTD. Overview 7
Key Facts 7
LG Life Science LTD. - Research and Development Overview 8
Key Therapeutic Areas 8
LG Life Science LTD. - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Combination Treatment Modalities 14
Pipeline Products - Partnered Products 15
Partnered Products/Combination Treatment Modalities 16
Pipeline Products - Out-Licensed Products 17
Out-Licensed Products/Combination Treatment Modalities 18
LG Life Science LTD. - Pipeline Products Glance 19
LG Life Science LTD. - Late Stage Pipeline Products 19
Pre-Registration Products/Combination Treatment Modalities 19
Phase III Products/Combination Treatment Modalities 20
LG Life Science LTD. - Clinical Stage Pipeline Products 21
Phase II Products/Combination Treatment Modalities 21
Phase I Products/Combination Treatment Modalities 22
LG Life Science LTD. - Early Stage Pipeline Products 23
Preclinical Products/Combination Treatment Modalities 23
Discovery Products/Combination Treatment Modalities 24
LG Life Science LTD. - Unknown Stage Pipeline Products 25
Unknown Products/Combination Treatment Modalities 25
LG Life Science LTD. - Drug Profiles 26
(gemigliptin + glimepiride) - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
(gemigliptin + metformin hydrochloride) - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
(gemigliptin + rosuvastatin calcium) - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
(lercanidipine hydrochloride + valsartan) - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
adalimumab biosimilar - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
etanercept biosimilar - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Eupenta - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
exenatide SR - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
infliximab biosimilar - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
interferon alfa-2a SR - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
LBDE - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
LBVC - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
LBVD - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
LBVE-013 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
LBVE-014 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
LC-231306 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
LC-280126 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
LC-280391 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
LC-34AD3 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
LC-350189 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
LC-541239 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
LC-65AOD3 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
LD-02GIFRO - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Monoclonal Antibody to Inhibit VEGF for Cancer - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NecX - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
nivocasan - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
rituximab biosimilar - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Small Molecule to Inhibit PAR-1 for Atherothrombosis - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecules for Obesity - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
somatropin - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
somatropin SR - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
LG Life Science LTD. - Pipeline Analysis 59
LG Life Science LTD. - Pipeline Products by Target 59
LG Life Science LTD. - Pipeline Products by Route of Administration 62
LG Life Science LTD. - Pipeline Products by Molecule Type 63
LG Life Science LTD. - Pipeline Products by Mechanism of Action 64
LG Life Science LTD. - Dormant Projects 67
LG Life Science LTD. - Locations And Subsidiaries 68
Head Office 68
Other Locations & Subsidiaries 68

Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 70
Disclaimer 71

List of Tables

LG Life Science LTD., Key Facts 7
LG Life Science LTD. - Pipeline by Indication, 2016 10
LG Life Science LTD. - Pipeline by Stage of Development, 2016 12
LG Life Science LTD. - Monotherapy Products in Pipeline, 2016 13
LG Life Science LTD. - Combination Treatment Modalities in Pipeline, 2016 14
LG Life Science LTD. - Partnered Products in Pipeline, 2016 15
LG Life Science LTD. - Partnered Products/ Combination Treatment Modalities, 2016 16
LG Life Science LTD. - Out-Licensed Products in Pipeline, 2016 17
LG Life Science LTD. - Out-Licensed Products/ Combination Treatment Modalities, 2016 18
LG Life Science LTD. - Pre-Registration, 2016 19
LG Life Science LTD. - Phase III, 2016 20
LG Life Science LTD. - Phase II, 2016 21
LG Life Science LTD. - Phase I, 2016 22
LG Life Science LTD. - Preclinical, 2016 23
LG Life Science LTD. - Discovery, 2016 24
LG Life Science LTD. - Unknown, 2016 25
LG Life Science LTD. - Pipeline by Target, 2016 60
LG Life Science LTD. - Pipeline by Route of Administration, 2016 62
LG Life Science LTD. - Pipeline by Molecule Type, 2016 63
LG Life Science LTD. - Pipeline Products by Mechanism of Action, 2016 65
LG Life Science LTD. - Dormant Developmental Projects,2016 67
LG Life Science LTD., Other Locations 68
LG Life Science LTD., Subsidiaries 69